

=> fil cap

FILE 'CAPLUS' ENTERED AT 09:56:01 ON 17 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2007 VOL 147 ISS 17

FILE LAST UPDATED: 16 Oct 2007 (20071016/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> d que 122

L1 STR

Ak@19 CH2-CH2-O @20 21 @22 CH2-CH2-O~CH2-CH2-O @23 24 25 26 27 @28 O~Ak @51 52 NH~Ak @53 54

CH2-CH2-O~CH2-CH2-O~CH2-CH2-O @29 30 31 32 33 34 35 36 @37 Ak~N~Ak 55 @56 57 S~Ak @58 59 Ak @6

CH2-CH2-O~CH2-CH2-O~CH2-O~C~CH2-CH2-O @38 39 40 41 42 43 44 45 46 47 48 @49 O~CF3 @60 61



Page 1-A

2

Page 1-B

VAR G1=19/20-15 22-50/23-15 28-50/29-15 37-50/38-15 49-50

VAR G2=H/OH/62/51/NH2/53/56/SH/58/NO2/CF3/60/X

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 19

CONNECT IS E1 RC AT 52

CONNECT IS E1 RC AT 54
 CONNECT IS E1 RC AT 55
 CONNECT IS E1 RC AT 57
 CONNECT IS E1 RC AT 59
 CONNECT IS E1 RC AT 62
 DEFAULT MLEVEL IS ATOM
 GGCAT IS LIN LOC SAT AT 19
 GGCAT IS UNS AT 50
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 62

STEREO ATTRIBUTES: NONE

L3 5 SEA FILE=REGISTRY SSS FUL L1
 L4 4 SEA FILE=CAPLUS ABB=ON PLU=ON L3
 L11 104 SEA FILE=CAPLUS ABB=ON PLU=ON ("ROIFMAN C"/AU OR "ROIFMAN C M"/AU OR "ROIFMAN CHAIM"/AU OR "ROIFMAN CHAIM M"/AU)
 L12 101 SEA FILE=CAPLUS ABB=ON PLU=ON ("DEMIN P"/AU OR "DEMIN P A"/AU OR "DEMIN P I"/AU OR "DEMIN P M"/AU OR "DEMIN P P"/AU OR "DEMIN PETER"/AU OR "DEMIN PETER M"/AU OR "DEMIN PETR M"/AU)
 L13 29 SEA FILE=CAPLUS ABB=ON PLU=ON ("GRUNBERGER T"/AU OR "GRUNBERGER THOMAS"/AU OR "GRUNBERGER TOM"/AU)
 L14 13 SEA FILE=CAPLUS ABB=ON PLU=ON ("ROUNOVA OLGA"/AU OR "ROUNOVA OLGA B"/AU)
 L15 2 SEA FILE=CAPLUS ABB=ON PLU=ON "CIMPEAN OCTAVIAN LAURAND"/AU
 L16 209 SEA FILE=CAPLUS ABB=ON PLU=ON (L11 OR L12 OR L13 OR L14 OR L15)
 L17 45 SEA FILE=CAPLUS ABB=ON PLU=ON L16 AND ?PROLIF?
 L18 44 SEA FILE=CAPLUS ABB=ON PLU=ON L17 AND ?CELL?
 L20 8 SEA FILE=CAPLUS ABB=ON PLU=ON L18 AND ?MODUL?
 L21 3 SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND L20
 L22 4 SEA FILE=CAPLUS ABB=ON PLU=ON L4 OR L21

=> d l22 ibib abs hitstr tot

L22 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1075808 CAPLUS Full-text

DOCUMENT NUMBER: 143:346899

TITLE: Preparation of styrylacrylonitrile derivatives as modulators of cell proliferation

INVENTOR(S): Roifman, Chaim M.; Demin, Peter; Freywald, Andrew; Grunberger, Thomas; Rounova, Olga; Sharfe, Nigel

PATENT ASSIGNEE(S): HSC Research and Development Limited Partnership, Can.

SOURCE: PCT Int. Appl., 181 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092904	A1	20051006	WO 2005-CA423	20050322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

CA 2560584 A1 20051006 CA 2005-2560584 20050322

EP 1727822 A1 20061206 EP 2005-729066 20050322

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:



US 2004-556972P P 20040326

US 2005-649211P P 20050202

WO 2005-CA423 W 20050322

OTHER SOURCE(S): MARPAT 143:346899

GI



AB Title compds. I [R1 and R2 independently = H, OH, alkoxy, etc.; R3 = H, NH2, SH, etc.; R4 = NH2, NH-alkyl, P(O)(OH)2, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of cell proliferation. Thus, e.g., II was prepared by amidation of Me cyanoacetate with benzylamine followed by coupling with 3,4-dimethoxycinnamaldehyde (preparation given) and subsequent demethylation. The activity of II towards killing of Ly-MN cells was evaluated and it was found that it significantly inhibited cell proliferation and survival at nanomolar doses, and effected a inhibition by 2.5 μ M. I as modulator of cell proliferation should prove useful in the treatment of a variety of cancers such as leukemia and lymphoma. Pharmaceutical compns. comprising I are disclosed.

IT 569343-54-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of styrylacrylonitrile derivs. as modulators of cell proliferation)

RN 569343-54-0 CAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-,

phenylmethyl ester, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:120874 CAPLUS Full-text
 DOCUMENT NUMBER: 142:197698
 TITLE: Preparation of arylcyanopentadienoates as modulators of cell proliferation
 INVENTOR(S): Roifman, Chaïm M.; Demin, Peter; Rounova, Olga; Grunberger, Thomas; Cimpean, Octavian Laurand
 PATENT ASSIGNEE(S): The Hospital for Sick Children, Can.
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012234	A1	20050210	WO 2004-CA1431	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2533287	A1	20050210	CA 2004-2533287	20040730
EP 1654220	A1	20060510	EP 2004-738022	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2007197660	A1	20070823	US 2006-566815	20061204
PRIORITY APPLN. INFO.:			US 2003-491109P	P 20030730
			WO 2004-CA1431	W 20040730
OTHER SOURCE(S):		CASREACT 142:197698; MARPAT 142:197698		
GI				



I

AB Title compds. [I; Q = CO₂XR₄, SO₂R₅; R₁, R₂, R₃ = H, OH, alkyl, alkoxy, alkylcarbonyloxy, amino, alkylcarbonylamino, SH, alkylthio, NO₂, CF₂, OCF₃, halo, etc.; R₄ = (substituted) aryl; R₅ = alkyl, (substituted) Ph, pyridyl; X = (CH₂CH₂O)_n, (CH₂)_n; n = 1-4; with provisos], were prepared Thus, 2-(4-chlorobenzenesulfonyl)-5-(3,4-dihydroxyphenyl)penta-2E,4E- dienenitrile (CRVIII-51) (preparation via Knoevenagel reaction outlined) killed Z119 acute lymphoblastic leukemia cells with IC₅₀ = 0.23 μM.

IT 569343-54-0P 569343-56-2P 569343-66-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of arylcyanopentadienoates as modulators of cell proliferation)

RN 569343-54-0 CAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, phenylmethyl ester, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 569343-56-2 CAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(3,4-dihydroxyphenyl)-, phenylmethyl ester, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.





RN 569343-66-4 CAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3-methoxyphenyl)-, phenylmethyl ester, (2E,4E)- (CA INDEX NAME)

OTHER SOURCE(S):

MARPAT 139:133348

GI



AB Title compds. I and II [R1-R3 = H, OH, alkyl, alkoxy, (un)substituted NH₂, SH, alkylthio, NO₂, CF₃, OCF₃, halo; R4 = (un)substituted aryl; X = (CH₂CH₂O)_n, (CH₂)_n; n = 1-4] were prepared. Thus, 3,4-(Me₃CMe₂SiO)₂C₆H₃CH:CHCH₂OH was oxidized and desilylated to give caffeoylaldehyde which was treated with benzyl cyanoacetate to give I [R1, R2 = OH, X = CH₂, R3 = H, R4 = Ph] which had IC₅₀ for inhibition of AML-3 acute myeloid leukemia in vitro of 0.09 μM.

IT 569343-54-0P 569343-56-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpentadienoates for modulating cell proliferation)

RN 569343-54-0 CAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-, phenylmethyl ester, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 569343-56-2 CAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(3,4-dihydroxyphenyl)-, phenylmethyl ester, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




IT 569343-66-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpentadienoates for modulating cell proliferation)

RN 569343-66-4 CAPLUS

CN 2,4-Pentadienoic acid, 2-cyano-5-(4-hydroxy-3-methoxyphenyl)-, phenylmethyl ester, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:180915 CAPLUS Full-text

DOCUMENT NUMBER: 134:215000

TITLE: Method of forming liquid crystal display orientation film without rubbing process

INVENTOR(S): Sakai, Takeya; Uetsuki, Masao; Kawatsuki, Yoshihiro

PATENT ASSIGNEE(S): Hayashi Telempu Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001066605	A	20010316	JP 1999-242421	19990830
TW 500747	B	20020901	TW 2000-89100508	20000114
US 6696114	B1	20040224	US 2000-484698	20000118
KR 2000053526	A	20000825	KR 2000-2339	20000119
PRIORITY APPLN. INFO.:			JP 1999-9997	A 19990119
			JP 1999-74898	A 19990319
			JP 1999-223916	A 19990806
			JP 1999-242421	A 19990830
			JP 1999-300455	A 19991022

GI



AB The process comprises the steps of (1) applying a polymer having a repeating unit I, II, III, or IV (R1-5 = H, halo, methoxy, alkyloxy; R6-9 = H, CN, Ph, phenoxy, Me alkyl, methoxy, alkyloxy) on a substrate and (2) obliquely irradiating the polymer film with polarized light. The process without a rubbing process eliminated the generation of dusts.

IT 328309-03-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(method of forming liquid crystal display orientation film without rubbing process)

RN 328309-03-1 CAPLUS


CN 2,4-Pentadienoic acid, 2-cyano-5-phenyl-, 2-[[4'-[[6-[(2-methyl-1-oxo-2-propenyl)oxy]hexyl]oxy][1,1'-biphenyl]-4-yl]oxy]ethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1


CRN 328309-02-0

CMF C36 H37 N O6

PAGE 1-A



PAGE 1-B



=> d que 123


L1

STR

Ak @19

CH2-CH2-O
@20 21 @22CH2-CH2-O-CH2-CH2-O
@23 24 25 26 27 @28O-Ak
@51 52NH-Ak
@53 54CH2-CH2-O-CH2-CH2-O-CH2-CH2-O
@29 30 31 32 33 34 35 36 @37Ak-N-Ak
55 @56 57S-Ak
@58 59

Ak @6

CH2-CH2-O-CH2-CH2-O-CH2-O-C-CH2-CH2-O
@38 39 40 41 42 43 44 45 46 47 48 @49O-CF3
@60 61

Page 1-A

2

Page 1-B

VAR G1=19/20-15 22-50/23-15 28-50/29-15 37-50/38-15 49-50

VAR G2=H/OH/62/51/NH2/53/56/SH/58/NO2/CF3/60/X

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 19

CONNECT IS E1 RC AT 52

CONNECT IS E1 RC AT 54

CONNECT IS E1 RC AT 55

CONNECT IS E1 RC AT 57

CONNECT IS E1 RC AT 59

CONNECT IS E1 RC AT 62

DEFAULT MLEVEL IS ATOM

GGCAT IS LIN LOC SAT AT 19

GGCAT IS UNS AT 50

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 62

STEREO ATTRIBUTES: NONE

L3 5 SEA FILE=REGISTRY SSS FUL L1

L4 4 SEA FILE=CAPLUS ABB=ON PLU=ON L3

L11 104 SEA FILE=CAPLUS ABB=ON PLU=ON ("ROIFMAN C"/AU OR "ROIFMAN C M"/AU OR "ROIFMAN CHAIM"/AU OR "ROIFMAN CHAIM M"/AU)

L12 101 SEA FILE=CAPLUS ABB=ON PLU=ON ("DEMIN P"/AU OR "DEMIN P A"/AU OR "DEMIN P I"/AU OR "DEMIN P M"/AU OR "DEMIN P P"/AU OR

"DEMIN PETER"/AU OR "DEMIN PETER M"/AU OR "DEMIN PETR M"/AU)
 L13 29 SEA FILE=CAPLUS ABB=ON PLU=ON ("GRUNBERGER T"/AU OR "GRUNBERGER THOMAS"/AU OR "GRUNBERGER TOM"/AU)
 L14 13 SEA FILE=CAPLUS ABB=ON PLU=ON ("ROUNOVA OLGA"/AU OR "ROUNOVA OLGA B"/AU)
 L15 2 SEA FILE=CAPLUS ABB=ON PLU=ON "CIMPEAN OCTAVIAN LAURAND"/AU
 L16 209 SEA FILE=CAPLUS ABB=ON PLU=ON (L11 OR L12 OR L13 OR L14 OR L15)
 L17 45 SEA FILE=CAPLUS ABB=ON PLU=ON L16 AND ?PROLIF?
 L18 44 SEA FILE=CAPLUS ABB=ON PLU=ON L17 AND ?CELL?
 L20 8 SEA FILE=CAPLUS ABB=ON PLU=ON L18 AND ?MODUL?
 L21 3 SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND L20
 L23 5 SEA FILE=CAPLUS ABB=ON PLU=ON L20 NOT L21

=> d l23 ibib abs tot

L23 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:232306 CAPLUS Full-text

DOCUMENT NUMBER: 144:292410

TITLE: Conjugated arylalkenyl nitriles as modulators of abnormal cell proliferation, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Roifman, Chaim; Demin, Peter; Rounova, Olga; Grunberger, Tom

PATENT ASSIGNEE(S): The Hospital for Sick Children, Can.

SOURCE: U.S. Pat. Appl. Publ., 17 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006058297	A1	20060316	US 2004-940009	20040914
CA 2580601	A1	20060323	CA 2005-2580601	20050914
WO 2006029515	A1	20060323	WO 2005-CA1394	20050914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1797064	A1	20070620	EP 2005-786685	20050914
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2004-940009	A 20040914
			WO 2005-CA1394	W 20050914

OTHER SOURCE(S): MARPAT 144:292410

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to conjugated nitriles I and II, which are modulators of abnormal cell proliferation, including cancer. In compds. I and II; X is H or halo; R1, R2, and R3 are independently selected from H, OH, C1-6 alkyl, C1-6 alkoxy, C2-7 acyloxy, NH2, C1-6 alkylamino, etc.; R4 is C(O)R5, C(S)R5, SO2-aryl, NH2, NH-C1-6 alkyl, etc.; R5 is OH, NH2, C1-6 alkoxy, aryloxy, arylamino, aryl-C1-6 alkyl-amino, C1-6 alkyl, etc.; A is a bond or ethenylene; B is a bond, phenylene, or pyridinylene; and Ar is Ph, pyridinyl, pyrazinyl, pyrimidinyl, imidazolyl, furyl, or thienyl, optionally substituted with 1-4 substituents; provided that when A is ethenylene, X is H. The invention also relates to the preparation of I and II, pharmaceutical compns. comprising a compound I or II, together with a pharmaceutically acceptable carrier, as well as to the use of the compns. for modulating abnormal cell proliferation, including cancer. Amidation of Me cyanoacetate with veratrylamine (3,4-dimethoxybenzylamine) and demethylation gave cyanoacetamide III, which underwent Knoevenagel condensation with (Z)-IV, resulting in the formation of (E,Z)-arylalkenyl nitrile V. The compds. of the invention are modulators of abnormal cell proliferation, e.g., compound V expresses an IC50 value of less than 125 nM towards Z119 acute lymphoblastic leukemia cells.

L23 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:231410 CAPLUS Full-text

DOCUMENT NUMBER: 144:292409

TITLE: Phenylpentadienamides as modulators of abnormal cell proliferation, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Roifman, Chaim; Demin, Peter; Rounova, Olga; Grunberger, Tom

PATENT ASSIGNEE(S): The Hospital for Sick Children, Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent.

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006058554	A1	20060316	US 2004-940010	20040914
US 7202383	B2	20070410		
CA 2580979	A1	20060323	CA 2005-2580979	20050914
WO 2006029516	A1	20060323	WO 2005-CA1395	20050914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1807386	A1	20070718	EP 2005-784997	20050914

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

US 2007185123

A1

20070809

US 2007-723261

20070319

PRIORITY APPLN. INFO.:

US 2004-940010

A 20040914


WO 2005-CA1395

W 20050914


OTHER SOURCE(S):

CASREACT 144:292409; MARPAT 144:292409


GI



I



II



III

AB The invention relates to 5-phenylpentadienamides I, which are modulators of abnormal cell proliferation, including cancer. In compds. I; R1, R2, and R3 are independently selected from H, OH, halo, C1-6 alkyl, C1-6 alkoxy, C2-7 acyloxy, NH2, C1-6 alkylamino, etc.; and Ar is (un)substituted aryl or (un)substituted heteroaryl; including salts and solvates thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, together with a pharmaceutically acceptable carrier, as well as to the use of the compns. for modulating abnormal cell proliferation, including cancer. Wittig reaction of (E)-4-acetoxy-3-methoxycinnamaldehyde with Me (triphenylphosphoranylidene)acetate gave (E,E)-phenylpentadienoate II, which underwent hydrolysis, amidation with benzylamine and demethylation to give (E,E)-phenylpentadienamide III. The compds. of the invention are modulators of abnormal cell proliferation, e.g., compound III expresses an IC50 value of 0.46 μ M towards Z119 acute lymphoblastic leukemia cells.

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:780841 CAPLUS Full-text

DOCUMENT NUMBER: 135:318329

TITLE: Novel compounds for modulating cell proliferation

INVENTOR(S): Roifman, Chaim M.; Grunberger, Thomas; Rounova, Olga; Demin, Peter; Sharfe, Nigel

PATENT ASSIGNEE(S): Hsc Research and Development Limited Partnership, Can.
 SOURCE: PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079158	A2	20011025	WO 2001-CA516	20010412
WO 2001079158	A3	20020131		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406160	A1	20011025	CA 2001-2406160	20010412
AU 200148201	A	20011030	AU 2001-48201	20010412
EP 1272457	A2	20030108	EP 2001-921087	20010412
EP 1272457	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
GB 2378948	A	20030226	GB 2002-26316	20010412
GB 2378948	B	20041110		
US 2003109502	A1	20030612	US 2001-834728	20010412
US 6800659	B2	20041005		
JP 2003531133	T	20031021	JP 2001-576760	20010412
BR 2001010087	A	20040217	BR 2001-10087	20010412
RU 2277531	C2	20060610	RU 2002-127415	20010412
AT 337296	T	20060915	AT 2001-921087	20010412
EP 1752446	A2	20070214	EP 2006-17078	20010412
EP 1752446	A3	20070321		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
ES 2267747	T3	20070316	ES 2001-1921087	20010412
IN 2002DN00999	A	20050128	IN 2002-DN999	20021007
MX 2002PA10089	A	20040819	MX 2002-PA10089	20021011
HK 1052496	A1	20061110	HK 2003-104797	20030707
US 2004072803	A1	20040415	US 2003-240740	20031027
US 7012095	B2	20060314		
US 2004209845	A1	20041021	US 2004-803607	20040317
PRIORITY APPLN. INFO.:				
			US 2000-196936P	P 20000413
			EP 2001-921087	A3 20010412
			US 2001-834728	A1 20010412
			WO 2001-CA516	W 20010412

OTHER SOURCE(S): MARPAT 135:318329

AB Novel styrylacrylonitrile compds. which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed. Thus, (E,E)-2-(benzylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile, prepared in 62% yield by condensation of 3,4-dimethoxycinnamaldehyde with N-(cyanoacetyl)benzylamine, was demethylated with BBr₃ to give 55% (E,E)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile, useful in treating a variety of cell proliferative disorders. Approx. 30 other styrylacrylonitriles were similarly prepared

L23 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:507754 CAPLUS Full-text
 DOCUMENT NUMBER: 135:91546
 TITLE: Methods of modulation of the immune system
 INVENTOR(S): Roifman, Chaim M.; Freywald, Andrew; Sharfe, Nigel; Grunberger, Thomas; Grunebaum, Eyal
 PATENT ASSIGNEE(S): The Hospital for Sick Children, Can.
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049743	A2	20010712	WO 2001-CA4	20010105
WO 2001049743	A3	20020418		
WO 2001049743	A9	20021205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2396114	A1	20010712	CA 2001-2396114	20010105
EP 1246637	A2	20021009	EP 2001-901074	20010105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003113328	A1	20030619	US 2002-169520	20021026
US 7205113	B2	20070417		
US 2007218070	A1	20070920	US 2007-712995	20070302
PRIORITY APPLN. INFO.:				
			US 2000-174710P	P 20000106
			WO 2001-CA4	W 20010105
			US 2002-169520	A3 20021026

AB Manipulation of the EphB6 receptor and its active Eph partners allow for regulation of T cell responses, including TCR signalling, T cell proliferation, and induction of T cell death. Methods of modulating EphB6 are described as well as various therapeutic applications.

L23 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1988:568578 CAPLUS Full-text
 DOCUMENT NUMBER: 109:168578
 TITLE: Functional differences between immunoglobulins M and D expressed on the surface of an immature B-cell line
 AUTHOR(S): Tisch, Roland; Roifman, Chaim M.; Hozumi, Nobumichi
 CORPORATE SOURCE: Res. Inst., Mount Sinai Hosp., Toronto, ON, M5G 1X5, Can.
 SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1988), 85(18), 6914-18
 CODEN: PNASA6; ISSN: 0027-8424
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Crosslinked IgM mols. expressed on the surface of immature B cells mediate responses that inhibit further development, in contrast to the activational and proliferative events that follow crosslinking of the μ heavy chain in mature B cells. Concomitant with this change in IgM signaling capacity is the appearance of surface IgD, which has been proposed to modulate the response elicited by the μ heavy chain. In an attempt to gain insight into the mechanism(s) by which surface IgM is able to generate such disparate responses, δ heavy chain gene transfectants of the murine B-cell lymphoma line WEHI-231 were established. WEHI-231 cells resemble phenotypically immature B cells, in addition to being highly susceptible to the growth-inhibitory effect of surface IgM crosslinking. Endogenous μ and exogenous δ heavy chains expressed on the surface of the transfectants were compared for their role in cell proliferation and on gene expression. The results indicate that the growth-inhibitory response is associated only with the μ heavy chain and that surface IgD does not mediate such a response. Furthermore, in contrast to IgM, IgD mols. appear to have an inductive effect on the expression of Myc and the endogenous μ and exogenous δ Ig heavy chain genes but not on the expression of the housekeeping gene encoding β 2-microglobulin. Apparently, IgM and IgD are functionally distinct when expressed on the surface of an immature B cell.

=> fil marpat

FILE 'MARPAT' ENTERED AT 09:56:28 ON 17 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT..

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 147 ISS 16 (20071012/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2007207949 06 SEP 2007

DE 102006007895 30 AUG 2007

EP 1826829 29 AUG 2007

JP 2007221039 30 AUG 2007

WO 2007101371 13 SEP 2007

GB 2435041 15 AUG 2007

FR 2897532 24 AUG 2007



RU 2304584 20 AUG 2007

CA 2537669 24 AUG 2007

Expanded G-group definition display now available.

=> d que 110

L1 STR



Page 1-A

2

Page 1-B

VAR G1=19/20-15 22-50/23-15 28-50/29-15 37-50/38-15 49-50

VAR G2=H/OH/62/51/NH2/53/56/SH/58/NO2/CF3/60/X

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 19

CONNECT IS E1 RC AT 52

CONNECT IS E1 RC AT 54

CONNECT IS E1 RC AT 55

CONNECT IS E1 RC AT 57

CONNECT IS E1 RC AT 59

CONNECT IS E1 RC AT 62

DEFAULT MLEVEL IS ATOM

GGCAT IS LIN LOC SAT AT 19

GGCAT IS UNS AT 50

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 62

STEREO ATTRIBUTES: NONE

L3 5 SEA FILE=REGISTRY SSS FUL L1

L4 4 SEA FILE=CAPLUS ABB=ON PLU=ON L3

L8 8 SEA FILE=MARPAT SSS FUL L1

L9 8 SEA FILE=MARPAT ABB=ON PLU=ON L8/COM

L10 6 SEA FILE=MARPAT ABB=ON PLU=ON L9 NOT L4

=> d l10 ibib abs ghit tot

L10 ANSWER 1 OF 6 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 146:212257 MARPAT Full-text

TITLE: Use of merocyanine derivatives as stabilizers for

body-care and household products
 INVENTOR(S): Wagner, Barbara; Reich, Oliver
 PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
 SOURCE: PCT Int. Appl., 85pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014848	A2	20070208	WO 2006-EP64388	20060719
WO 2007014848	A3	20070503		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2005-107026 20050729
 EP 2006-100600 20060119

AB Described is the use of specific merocyanine derivs. for protecting body-care and household products from photolytic and oxidative degradation. These compds. perform outstanding UV absorber properties.

MSTR 1B

G1—G2


G2 = 3

G3—G4


G4 = 5

G6—G33

G6 = 345-3 347-8




G7 = CN / 28




G8 = 44




G10 = 115



G25 = 367



G33 = 425



Patent location:

Note:

Note:

claim 1

additional ring formation also claimed

additional substitution also claimed


L10 ANSWER 2 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 143:179662 MARPAT Full-text
 TITLE: Pharmaceutical composition comprising hydroxylphenyl derivatives of rosmarinic acid for cancer treatment
 INVENTOR(S): Won, Jonghwa; Hur, Yun-Gyoung; Kim, Sung-Joo; Park, See-Hyoung; Park, Doohong
 PATENT ASSIGNEE(S): Mogam Biotechnology Research Institute, S. Korea
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072723	A1	20050811	WO 2004-KR1597	20040630
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

KR 2005078743 A 20050808 KR 2004-6548 20040202

PRIORITY APPLN. INFO.: KR 2004-6548 20040202


AB The present invention relates to a pharmaceutical composition for cancer treatment containing hydroxylphenyl derivs. of rosmarinic acid as an effective ingredient. Hydroxylphenyl derivs. of rosmarinic acid of the present invention strongly induce apoptosis of T-cell derived leukemia cells and even B-cell derived leukemia cells expressing Lck abnormally. However, they do not elicit apoptosis of other cell lines originated from B-cells and monocytes, which usually do not express Lck. While hydroxylphenyl derivs. of rosmarinic acid of the present invention do not induce apoptosis of peripheral blood mononuclear cells from healthy donors, they induce apoptosis of peripheral blood mononuclear cells from leukemia patients. When hydroxyl groups in the Ph rings of rosmarinic acid are eliminated or masked, the apoptotic activity is removed, indicating that hydroxyl groups of Ph rings located in both ends of rosmarinic acid are indispensable for apoptosis. Thus, an injectable solution was prepared containing hydroxylphenyl derivative of rosmarinic acid 1 g, sodium chloride 0.6 g, ascorbic acid 0.1 g and distilled water. Hydroxylphenyl derivative of rosmarinic acid effectively destroyed T-cell leukemia cell lines (Jurkat, H9, CCRF-CEM) and B-cell leukemia cell line, BCL-1, expressing Lck abnormally, showing ED50 of 12 μ M. Hydroxylphenyl derivative of rosmarinic acid also killed other leukemia cell lines not expressing Lck. Hydroxylphenyl derivs. of rosmarinic acid of the present invention are expected to induce apoptosis of cancer cells but not normal cells, so that they can be effectively used for preventing and treating cancers.



G3 = O
G4 = 37



G5 = O
G6 = G7 / G10
G7 = (0-2) 41-13 42-15



G8 = CN
G10 = (0-2) CH2

Patent location: claim 1

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 6 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 142:113707 MARPAT Full-text

TITLE: A preparation of cinnamaldehyde derivatives, useful for the preparation of α,β -unsaturated cyanoester and cyanoamide compounds

INVENTOR(S): Ruha, Olivier; Oswald, Thomas

PATENT ASSIGNEE(S): Lymphosign Inc., Can.

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000777	A2	20050106	WO 2004-IB2153	20040629
WO 2005000777	A3	20050414		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG


CH 696238	A5	20070228	CH 2003-1149	20030630
CA 2529086	A1	20050106	CA 2004-2529086	20040629
US 2005033090	A1	20050210	US 2004-880430	20040629
EP 1638912	A2	20060329	EP 2004-737208	20040629

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.:

CH 2003-1149	20030630
WO 2004-IB2153	20040629


OTHER SOURCE(S): CASREACT 142:113707
 GI



I

AB The invention relates to a preparation of cinnamaldehyde derivs. of formula I [wherein: X is O or NH], useful for the preparation of α,β -unsatd. cyanoester and cyanoamide compds. For instance, cinnamaldehyde derivative (E)-I (X = O) was prepared from 5-Bromo-2,2-dimethyl-1,3-benzodioxole and 2-vinyl-1,3-dioxolane via Heck reaction and subsequent cleavage with overall yield of 33%.

MSTR 4



G1 = OH

G2 = O

G3 = Ph (opt. substd.)


Patent location:

claim 18


Note:

substitution is restricted


MSTR 6



G9 = 119



G21 = 7



Patent location: claim 21
 Note: substitution is restricted
 Note: also incorporates claim 31, structure VIII

L10 ANSWER 4 OF 6 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 139:350938 MARPAT Full-text

TITLE: Preparation of N-cinnamoyl-DOPA esters and related compounds as T lymphocyte inhibitors

INVENTOR(S): Won, Jongwha; Lee, Keunhyeung; Park, Seehyoung; Kim, Sung-Joo; Yun, Su-Young; Kang, Mi-Ae; Hur, Yun-Gyoung; Youn, Jeehee; Yun, Yungdae; Park, Doohong; Oh, Jaetaek

PATENT ASSIGNEE(S): Mogam Biotechnology Research Institute, S. Korea

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089405	A1	20031030	WO 2003-KR751	20030414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004082664	A1	20040429	US 2003-411772	20030411
AU 2003221144	A1	20031103	AU 2003-221144	20030414
EP 1499585	A1	20050126	EP 2003-715837	20030414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1646480	A	20050727	CN 2003-808343	20030414
JP 2005522523	T	20050728	JP 2003-586126	20030414
PRIORITY APPLN. INFO.:			KR 2002-20481	20020415

GI



AB Title compds. I [R1-R10 = H, OH, halogen, alkoxy, CHO, CO2H, NH2, CF3, NO2, \geq 1 of R1-R5 and R6-R10 = OH; X1 = O, S, NH, NMe, NEt, NHNH; X2 = CH2, CO, CS, CONH; X3 = bond, (un)substituted CH:CH, CH:CHCH:CH, CH2, CH2CH2; Y1 = H, CH2, CO, CS, alkyl, amino, 3-methyl-1,2,4-oxadiazol-5-yl, 3-benzyl-1,2,4-oxadiazol-5-yl; Y = absent, (un)substituted NH2, OH, SH; B = H, alkyl] were prepared as inhibitors of the activation of T lymphocytes by the src homol. region 2(SH2) domain of T lymphocyte (lck), useful for the treatment, prevention and/or diagnosis of graft rejection, autoimmune diseases, inflammatory diseases, etc. Thus, D-DOPA was converted to its Me ester and treated with caffeic acid to give the amide II which inhibited the binding of the lck SH2 domain with its cognate peptide < 10 μ M.

MSTR 1




G3 = O
G4 = 37

$_3C \equiv G5$

G5 = O

G6 = G7
 G7 = (0-2) 41-13 42-15



G8 = CN
 Patent location: claim 1


REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 121:95567 MARPAT Full-text
 TITLE: Photocrosslinkable materials usable as green or blue laser sources and frequency doubler comprising them
 INVENTOR(S): Le Barny, Pierre; Muller, Sophie; Lemoine, Vincent; Dubois, Jean Claude
 PATENT ASSIGNEE(S): Thomson-CSF, Fr.
 SOURCE: Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 567378	A1	19931027	EP 1993-400997	19930416
R: DE, GB, NL				
FR 2690446	A1	19931029	FR 1992-4924	19920422
PRIORITY APPLN. INFO.:			FR 1992-4924	19920422

AB These stable materials comprise a polymer containing a photocrosslinkable group, and a small active mol. having ≥ 2 photocrosslinkable functions identical to that of the polymer. A frequency doubler uses these materials and permits green or blue laser sources to be obtained.


MSTR 6



G1 = (2-5) CH2
 G2 = 28



G3 = O
G8 = 113




G9 = CN
Patent location: claim 4

L10 ANSWER 6 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 119:138910 MARPAT Full-text
TITLE: Preparation of α -cyanocinnamic acid esters as nonlinear optical materials
INVENTOR(S): Hidaka, Takahiro; Hayashi, Hideki; Nakatani, Hiroyuki
PATENT ASSIGNEE(S): Sekisui Chemical Co. Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05058980	A	19930309	JP 1991-314866	19911128
PRIORITY APPLN. INFO.:			JP 1990-331197	19901128
			JP 1991-147148	19910619
			JP 1991-147149	19910619


GI




AB The title compds. [I; R = CH₂EtMe, CHMe(CH₂)₅Me, CHMePh; R₁ = NH₂, NMe₂, NHAc; Z = CH:, CH:CHCH], which have good stability at room temperature, excellent stability against light, show large second harmonic generation (SHG) activity and fluorescence, and are also useful as organic luminescent materials and laser dyes, are prepared I can form single crystals lacking an inversion center of symmetry. Thus, esterification of NCCH₂CO₂H with (S)-sec-Bu alc. in the presence of H₂SO₄ in CH₂Cl₂ and condensation of the resultant (S)-sec-Bu

cyanoacetate with p-aminobenzaldehyde monomer in the presence of piperidine in refluxing benzene gave (S)-methylpropyl 2-cyano-3-(4-aminophenyl)-2-propenoate (II). When finely powdered crystals of II were irradiated with YAG laser, the SHG efficiency was comparable to that of urea, and green light of 532 nm with 1/2 the wavelength of the incoming light was observed. Addnl. 6 I were prepared and tested for SHG.


MSTR 1



G1 = NH₂
G2 = 15-25 17-29



G3 = 18



G4 = Ph
Patent location: claim 1

=> d'his nofil

(FILE 'HOME' ENTERED AT 09:31:41 ON 17 OCT 2007)

FILE 'REGISTRY' ENTERED AT 09:31:58 ON 17 OCT 2007

L1 STR
L2 0 SEA SSS SAM L1
L3 5 SEA SSS FUL L1
D SCA

FILE 'CAPLUS' ENTERED AT 09:43:32 ON 17 OCT 2007

L4 4 SEA ABB=ON PLU=ON L3

FILE 'BEILSTEIN' ENTERED AT 09:43:37 ON 17 OCT 2007

L5 0 SEA SSS SAM L1
L6 0 SEA SSS FUL L1

FILE 'MARPAT' ENTERED AT 09:48:26 ON 17 OCT 2007

L7 0 SEA SSS SAM L1
 L8 8 SEA SSS FUL L1
 L9 8 SEA ABB=ON PLU=ON L8/COM
 L10 6 SEA ABB=ON PLU=ON L9 NOT L4

FILE 'CAPLUS' ENTERED AT 09:48:55 ON 17 OCT 2007

E ROIFMAN C/AU
 L11 104 SEA ABB=ON PLU=ON ("ROIFMAN C"/AU OR "ROIFMAN C M"/AU OR
 "ROIFMAN CHAIM"/AU OR "ROIFMAN CHAIM M"/AU)
 E DEMIN P/AU
 L12 101 SEA ABB=ON PLU=ON ("DEMIN P"/AU OR "DEMIN P A"/AU OR "DEMIN
 P I"/AU OR "DEMIN P M"/AU OR "DEMIN P P"/AU OR "DEMIN PETER"/AU
 OR "DEMIN PETER M"/AU OR "DEMIN PETR M"/AU)
 E GRUNBERGER T/AU
 L13 29 SEA ABB=ON PLU=ON ("GRUNBERGER T"/AU OR "GRUNBERGER THOMAS"/A
 U OR "GRUNBERGER TOM"/AU)
 E ROUNOVA O/AU
 L14 13 SEA ABB=ON PLU=ON ("ROUNOVA OLGA"/AU OR "ROUNOVA OLGA B"/AU)
 E CIMPEAN O/AU
 L15 2 SEA ABB=ON PLU=ON "CIMPEAN OCTAVIAN LAURAND"/AU
 L16 209 SEA ABB=ON PLU=ON (L11 OR L12 OR L13 OR L14 OR L15)
 L17 45 SEA ABB=ON PLU=ON L16 AND ?PROLIF?
 L18 44 SEA ABB=ON PLU=ON L17 AND ?CELL?
 L19 8 SEA ABB=ON PLU=ON L18 AND ?MODULAT?
 L20 8 SEA ABB=ON PLU=ON L18 AND ?MODUL?
 L21 3 SEA ABB=ON PLU=ON L4 AND L20
 L22 4 SEA ABB=ON PLU=ON L4 OR L21
 L23 5 SEA ABB=ON PLU=ON L20 NOT L21

FILE 'CAPLUS' ENTERED AT 09:56:01 ON 17 OCT 2007

D QUE L22
 D L22 IBIB ABS HITSTR TOT
 D QUE L23
 D L23 IBIB ABS TOT

FILE 'MARPAT' ENTERED AT 09:56:28 ON 17 OCT 2007

D QUE L10
 D L10 IBIB ABS QHIT TOT